Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Montes

Ophthalmology San Juan, PR Medical Doctor

NPI 1518928498 CMS profile 1089660

735 Ave Ponce De Leon, Suite 813, San Juan, PR 00917

Open in the dashboard

General payments

$396,008

301 records reported · program years 2019–2025

Research payments

$22,629

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,395,243 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jose Montes of San Juan, PR is reported in the CMS Open Payments database as having received $396,008 across 301 general payments and $22,629 in research payments paid to them. Separately, studies naming them as principal investigator received $1,395,243 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $65,139 43
2024 General $108,800 51
2024 Research $22,629 6
2023 General $40,881 37
2022 General $48,930 34
2021 General $39,803 35
2020 General $50,468 26
2019 General $41,988 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Montes
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Jose Montes were reported at $65,139. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Jose Montes Ophthalmology median Middle half National median
2019 $41,988 $258 $104–$655 $163
2020 $50,468 $126 $45–$321 $114
2021 $39,803 $205 $76–$534 $132
2022 $48,930 $266 $100–$678 $149
2023 $40,881 $308 $117–$745 $160
2024 $108,800 $340 $127–$846 $164
2025 $65,139 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $148,408 86 payments
  2. Galderma Laboratories, L.P. $112,312 75 payments
  3. Allergan Inc. $88,646 73 payments
  4. Merz North America, Inc. $39,994 45 payments
  5. Galderma Research & Development, LLC $3,500 1 payment
  6. Endo Pharmaceuticals Inc. $2,923 18 payments
  7. Revance Therapeutics, Inc. $117 1 payment
  8. Lumenis, Inc $57 1 payment
  9. Alcon Vision LLC $52 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $214,439 54 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $122,181 40 payments
  3. Travel and Lodging $50,459 71 payments
  4. Food and Beverage $8,771 130 payments
  5. Education $80 4 payments
  6. Gift $77 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX $48,602 43 payments
  2. BOTOX COSMETIC $47,009 32 payments
  3. Xeomin $21,401 33 payments
  4. NATRELLE SALINE-FILLED BREAST IMPLANTS $3,500 1 payment
  5. KYBELLA $1,950 1 payment
  6. DYSPORT $129 2 payments
  7. DAXXIFY $117 1 payment
  8. Lumenis Pulse 120H $57 1 payment
  9. Clareon $52 1 payment
  10. RESTASIS $42 2 payments
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $22,629 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

160

Median for Ophthalmology: 891

Drug cost

$3,669

Median for Ophthalmology: $68,233

Branded share of claims

45%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorometholone Generic 21 $1,274
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 31 $1,198
Erythromycin Erythromycin Base Brand 41 $672
Dexamethasone Generic 35 $311
Losartan Potassium Generic 19 $121
Atorvastatin Calcium Generic 13 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $6,000
$6,000 — —
BOTOX
  • AbbVie, Inc. $4,577
$4,577 — —
DYSPORT
  • Galderma Laboratories, L.P. $129
$129 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

307 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record